Infographics

1. Small Molecule Drug Substance Outsourcing Drivers 10/4/2022

   ISR asked 57 respondents who outsource small molecule API which reason fits best with their company’s capacity for, and experience with, manufacturing small molecule drug substance. Read how the data shows the most common reason for outsourcing API manufacturing is a lack of capacity despite possessing in-house experience (42%).

    
2. Biologic Drug Substance Outsourcing Drivers 10/4/2022

   ISR data from Q2 2022 shows the most common reason for outsourcing bioprocessing is a lack of capacity despite possessing in-house experience (41%).

3. Top Therapeutic Areas For Highly Potent API 9/13/2022

   In Q1 of 2022, ISR asked 100 people who outsource highly potent drug substance what therapeutic areas their medications are designed to target. Discover the most common responses in this survey.

4. Outsourced Bioprocessing By Respondent Location 9/13/2022

   Europeans report outsourcing slightly more bioprocessing to China, while American respondents send more work to Japan and other Asia-Pacific manufacturing facilities (excluding China and India).

5. Desired Integrated Clinical Logistics Activities 8/15/2022

   Learn why clinical labeling, clinical supply chain management, and storage and distribution of clinical trial materials received the most votes in a survey of 100 sponsors outsourcing clinical logistics.

6. The Right Choice: Using Consultants For CDMO Selection 7/12/2022

   In Q2 2022, ISR asked 99 outsourcers whether the company they work for uses consultants to help guide their CDMO selection process. Read the results from ISR’s CDMO Outsourcing Models (3rd Edition) to gain insight into the use of consultants during CDMO selection.

7. HPAPI Outsourcing Drivers 7/12/2022

   In Q1 2022, ISR surveyed 100 sponsors who outsource highly potent small molecule drug substance manufacturing and asked them why their companies use CDMOs for the work. Uncover the data of how respondents are augmenting the supply they make in-house.

8. De-Risking The Supply Chain 6/14/2022

   124 sponsors who outsource small molecule drug substance were asked what strategies they are currently using or plan to use to de-risk their supply chain —a particularly pertinent topic in light of the events over the past few years, ranging from the COVID-19 pandemic to the conflict in the Ukraine.

9. Drug Innovators' Outlook On Innovative Treatments 6/14/2022

   134 outsourcers of biologic drug substance provided insight into their pipelines are impactingoutsourcing practices. Two-thirds (63%) said a focus on new, innovative treatments will impact outsourcing decisions.

10. Customer Loyalty In Small Molecule Drug Substance Manufacturing 5/4/2022

    ISR surveyed 124 sponsors who outsource small molecule drug product to gain insight into customer loyalty. Delve into the data of how the CMO loyalty is computed as an index that consists of overall satisfaction, willingness to recommend, and the likelihood of using the contract manufacturer again.